Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The endocannabinoid system in guarding against fear, anxiety and stress

  • Lutz, Beat
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Hillard, Cecilia J.
The endocannabinoid (eCB) system has emerged as a central integrator linking the perception of external and internal stimuli to distinct neurophysiological and behavioural outcomes (such as fear reaction, anxiety and stress-coping), thus allowing an organism to adapt to its changing environment. eCB signalling seems to determine the value of fear-evoking stimuli and to tune appropriate behavioural responses, which are essential for the organism's long-term viability, homeostasis and stress resilience; and dysregulation of eCB signalling can lead to psychiatric disorders. An understanding of the underlying neural cell populations and cellular processes enables the development of therapeutic strategies to mitigate behavioural maladaptation., B.L. was supported by the German Research Foundation (SFB TRR 58, CRC 1080 and FOR 926); G.M. by the Institut national de la santé et de la recherche médicale (INSERM), the European Commission Seventh Framework Programme (REPROBESITY, HEALTH-F2-2008-223713, PAINCAGE and HEALTH-2014-603191), the European Research Council (Endofood, ERC-2010-StG−260515, CannaPreg and ERC-2014-PoC-640923), the Fondation pour la Recherche Medicale (DRM20101220445), the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR Blanc NeuroNutriSens ANR-13-BSV4-0006 and BRAIN ANR-10-LABX-0043); R.M. by the grants SAF2014-59648P, RETICS-RTA#RD12/0028/0023, AGAUR#2014-SGR-1547 and Health-F2-2013-602891; and C.J.H. by the US National Institutes of Health grants DA038663, DA026996 and MH102838.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Srivastava, Raj Kamal
  • Cutando Ruiz, Laura, 1985-
  • Ortega Alvaro, Antonio
  • Ruehle, Sabine
  • Remmers, Floortje
  • Bindila, Laura
  • Bellochio, Luigi
  • Marsicano, Giovanni
  • Lutz, Beat
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Stressful events can generate emotional memories linked to the traumatic incident, but they also can impair the formation of nonemotional memories. Although the impact of stress on emotional memories is well studied, much less is known about the influence of the emotional state on the formation of nonemotional memories. We used the novel object-recognition task as a model of nonemotional memory in mice to investigate the underlying mechanism of the deleterious effect of stress on memory consolidation. Systemic, hippocampal, and peripheral blockade of cannabinoid type-1 (CB1) receptors abolished the stress-induced memory impairment. Genetic deletion and rescue of CB1 receptors in specific cell types revealed that the CB1 receptor population specifically in dopamine β-hydroxylase (DBH)-expressing cells is both necessary and sufficient for stress-induced impairment of memory consolidation, but CB1 receptors present in other neuronal populations are not involved. Strikingly, pharmacological manipulations in mice expressing CB1 receptors exclusively in DBH(+) cells revealed that both hippocampal and peripheral receptors mediate the impact of stress on memory consolidation. Thus, CB1 receptors on adrenergic and noradrenergic cells provide previously unrecognized cross-talk between central and peripheral mechanisms in the stress-dependent regulation of nonemotional memory consolidation, suggesting new potential avenues for the treatment of cognitive aspects on stress-related disorders., We acknowledge a predoctoral fellowship from the Spanish Ministry of Education and a postdoctoral fellowship from the Investments for the Future Programme, Initiative of Excellence Bordeaux, ANR-10-IDEX-03-02 (to A.B.-G.); a postdoctoral fellowship from the Marie Curie action Seventh Framework Programme for Research and Technological Development, FP7-PEOPLE-2013 (to A.B.-G.); the partial support by FRAXA Research Foundation (M.G.-G.); a European Molecular Biology Organization postdoctoral fellowship (to L. Bellocchio); grants from Ministerio de Ciencia e Innovación [BFU2012-33500 and BFU2015-68568P (to A.O.), and SAF2014-59648-P (to R.M.) (MINECO/FEDER, UE)]; Instituto de Salud Carlos III Grant RD06/0001/0001 (to R.M.); Generalitat de Catalunya Grant SGR-2014-1547 (to R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia (R.M.); the German Research Council DFG Grants FOR926 (Core Unit Endocannabinoid Measurements) (to B.L.), CRC-TRR58 (to B.L.), and CRC1080 (to B.L.); EU-FP7 Grant REPROBESITY, HEALTH-F2-2008-223713 (to B.L. and G.M.); PainCage Grant HEALTH-2013-INNOVATION-1-603191 (to G.M.); INSERM (G.M.); European Research Council Grant ENDOFOOD, ERC–2010–StG–260515 (to G.M.); Fondation pour la Recherche Medicale (G.M.); Region Aquitaine (G.M.); and LABEX BRAIN Grant ANR-10-LABX-43 (to G.M.)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Pregnenolone can protect the brain from cannabis intoxication

  • Vallée, Monique
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
  • Piazza, Pier Vincenzo
Pregnenolone is considered the inactive precursor of all steroid hormones, and its potential functional effects have been largely uninvestigated. The administration of the main active principle of Cannabis sativa (marijuana), Δ(9)-tetrahydrocannabinol (THC), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (CB1) receptor. Pregnenolone then, acting as a signaling-specific inhibitor of the CB1 receptor, reduces several effects of THC. This negative feedback mediated by pregnenolone reveals a previously unknown paracrine/autocrine loop protecting the brain from CB1 receptor overactivation that could open an unforeseen approach for the treatment of cannabis intoxication and addiction., Supported by the EU-FP7 (REPROBESITY, HEALTH-F2-2008-223713, G.M.), the European Research Council (ENDOFOOD, ERC-2010-StG-260515, G.M.), the Agence Nationale pour la Recherche (contracts HICOMET and TIMMS, P.V.P.), the U.S. National Institutes of Health (NIH) (grants DA-03672, DA-003934, and DA-09789, R.A.R. and G.L.B., and RO1 DA003934 and KO5 DA021358, P.H.R.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Differential control of cocaine self-administration by GABAergic and glutamatergic CB1 cannabinoid receptors

  • Martín García, Elena, 1975-
  • Bourgoin, Lucie
  • Cathala, Adeline
  • Kasanetz, Fernando
  • Mondesir, Miguel
  • Gutiérrez-Rodríguez, Ana
  • Reguero, Leire
  • Fiancette, Jean-François
  • Grandes, Pedro
  • Spampinato, Umberto
  • Maldonado, Rafael, 1961-
  • Piazza, Pier Vincenzo
  • Marsicano, Giovanni
  • Deroche-Gamonet, Véronique
The type 1 cannabinoid receptor (CB1) modulates numerous neurobehavioral processes and is therefore explored as a target for the treatment of several mental and neurological diseases. However, previous studies have investigated CB1 by targeting it globally, regardless of its two main neuronal localizations on glutamatergic and GABAergic neurons. In the context of cocaine addiction this lack of selectivity is critical since glutamatergic and GABAergic neuronal transmission is involved in different aspects of the disease. To determine whether CB1 exerts different control on cocaine seeking according to its two main neuronal localizations, we used mutant mice with deleted CB1 in cortical glutamatergic neurons (Glu-CB1) or in forebrain GABAergic neurons (GABA-CB1). In Glu-CB1, gene deletion concerns the dorsal telencephalon, including neocortex, paleocortex, archicortex, hippocampal formation and the cortical portions of the amygdala. In GABA-CB1, it concerns several cortical and non-cortical areas including the dorsal striatum, nucleus accumbens, thalamic, and hypothalamic nuclei. We tested complementary components of cocaine self-administration, separating the influence of primary and conditioned effects. Mechanisms underlying each phenotype were explored using in vivo microdialysis and ex vivo electrophysiology. We show that CB1 expression in forebrain GABAergic neurons controls mouse sensitivity to cocaine, while CB1 expression in cortical glutamatergic neurons controls associative learning processes. In accordance, in the nucleus accumbens, GABA-CB1 receptors control cocaine-induced dopamine release and Glu-CB1 receptors control AMPAR/NMDAR ratio; a marker of synaptic plasticity. Our findings demonstrate a critical distinction of the altered balance of Glu-CB1 and GABA-CB1 activity that could participate in the vulnerability to cocaine abuse and addiction. Moreover, these novel insights advance our understanding of CB1 neuropathophysiology., This work was supported by INSERM, the University of Bordeaux and the Aquitaine Region (to VDG, PVP, GM, UM), by the Fondation pour la Recherche Medicale (DRM20101220445), the Human Frontiers Science Program, and the Agence Nationale de la Recherche (ANR Blanc ANR-13BSV4–0006-02) (to GM), the DG Research of the European Commission FP7 [#HEALTH-F2 2013–602891 (to RM), HEALTH-60319 and ERC–2010–StG–260515 (to GM)], the Spanish ‘RETICS-Instituto de Salud Carlos III’ (#RD12/0028/0023), the Spanish ‘Ministerio de Ciencia e Innovación’ (#SAF2011–29864, no. SAF2011–29864, #SAF2013-40592-R, no. SAF2013-40592-R) and the Catalan Government ‘AGAUR-Generalitat de Catalunya’ (#2009SGR00731 and #2014-SGR-1547) (to RM), The Basque Government grant BCG IT764-13, Ministerio de Economía y Competitividad (MINECO) grant BFU2012-33334, University of the Basque Country UPV/EHU UFI11/41 and Red de Trastornos Adictivos - Instituto de Salud Carlos III grant RD12/0028/0004 (to PG). The FEDER funds support is also acknowledged. EM-G was supported by a ‘Sara Borrell’ post-doctoral fellowship from the Spanish ‘Instituto de Salud Carlos III’. FK was supported by an Aquitaine Region post-doctoral grant
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Dissociation of the pharmacological effects of THC by mTOR blockade

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
The potential therapeutic benefits of cannabinoid compounds have raised interest in understanding the molecular mechanisms that underlie cannabinoid-mediated effects. We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway. In the present study, we assess the relevance of the mTOR pathway in other acute and chronic pharmacological effects of THC. The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC. In contrast, THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception are not sensitive to the mTOR inhibition. In addition, a clear tolerance to THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception was observed after chronic treatment, but not to its anxiogenic- and amnesic-like effects. Temsirolimus pre-treatment prevented the amnesic-like effects of chronic THC without affecting the downregulation of CB1 receptors (CB1R) induced by this chronic treatment. Instead, temsirolimus blockade after chronic THC cessation did not prevent the residual cognitive deficit produced by chronic THC. Using conditional knockout mice lacking CB1R in GABAergic or glutamatergic neurons, we found that GABAergic CB1Rs are mainly downregulated under chronic THC treatment conditions, and CB1-GABA-KO mice did not develop cognitive deficits after chronic THC exposure. Therefore, mTOR inhibition by temsirolimus allows the segregation of the potentially beneficial effects of cannabinoid agonists, such as the anxiolytic and antinociceptive effects, from the negative effects, such as anxiogenic- and amnesic-like responses. Altogether, these results provide new insights for targeting the endocannabinoid system in order to prevent possible side effects., EP and AB-G were recipients of a predoctoral fellowship, Ministerio de Educación y Cultura. This work was supported by grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO and # SAF2011-29864 to RM), Instituto de Salud Carlos III (RD06/0001/0001 to RM), PLAN E/n(Plan Español para el Estímulo de la Economía y el Empleo), the European Commission/n(PHECOMP #LSHM-CT-2007-037669 to RM), Generalitat de Catalunya (SGR-2009-00731/nto RM), INSERM to GM, European Research Council (ENDOFOOD, ERC-2010-StG-/n260515, to GM), Fondation pour la Recherche Medicale to GM, and ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glucose metabolism links astroglial mitochondria to cannabinoid effects

  • Jimenez-Blasco, Daniel
  • Busquets-Garcia, Arnau
  • Hebert-Chatelain, Etienne
  • Serrat, Roman
  • Vicente-Gutiérrez, Carlos
  • Ioannidou, Christina
  • Gómez-Sotres, Paula
  • López-Fabuel, Irene
  • Resch-Beusher, Monica
  • Resel, Eva
  • Arnouil, Dorian
  • Saraswat, Dave
  • Varilh, Marjorie
  • Cannich, Astrid
  • Julio-Kalajzic, Francisca
  • Bonilla-Del Río, Itziar
  • Almeida, Angeles
  • Puente, Nagore
  • Achicallende, Svein
  • López-Rodríguez, María L.
  • Jollé, Charlotte
  • Déglon, Nicole
  • Pellerin, Luc
  • Josephine, Charlene
  • Bonvento, Gilles
  • Panatier, Aude
  • Lutz, Beat
  • Piazza, Pier Vincenzo
  • Guzmán, Manuel
  • Bellocchio, Luigi
  • Bouzier-Sore, Anne-Karine
  • Grandes, Pedro
  • Bolaños, Juan P.
  • Marsicano, Giovanni
Astrocytes take up glucose from the bloodstream to provide energy to the brain, thereby allowing neuronal activity and behavioural responses1,2,3,4,5. By contrast, astrocytes are under neuronal control through specific neurotransmitter receptors5,6,7. However, whether the activation of astroglial receptors can directly regulate cellular glucose metabolism to eventually modulate behavioural responses is unclear. Here we show that activation of mouse astroglial type-1 cannabinoid receptors associated with mitochondrial membranes (mtCB1) hampers the metabolism of glucose and the production of lactate in the brain, resulting in altered neuronal functions and, in turn, impaired behavioural responses in social interaction assays. Specifically, activation of astroglial mtCB1 receptors reduces the phosphorylation of the mitochondrial complex I subunit NDUFS4, which decreases the stability and activity of complex I. This leads to a reduction in the generation of reactive oxygen species by astrocytes and affects the glycolytic production of lactate through the hypoxia-inducible factor 1 pathway, eventually resulting in neuronal redox stress and impairment of behavioural responses in social interaction assays. Genetic and pharmacological correction of each of these effects abolishes the effect of cannabinoid treatment on the observed behaviour. These findings suggest that mtCB1 receptor signalling can directly regulate astroglial glucose metabolism to fine-tune neuronal activity and behaviour in mice., This work was funded by: INSERM, the European Research Council (Endofood, ERC–2010–StG–260515 and CannaPreg, ERC-2014-PoC-640923, MiCaBra, ERC-2017-AdG-786467), Fondation pour la Recherche Medicale (FRM, DRM20101220445), the Human Frontiers Science Program, Region Nouvelle Aquitaine and Agence Nationale de la Recherche (ANR; NeuroNutriSens ANR-13-BSV4-0006, CaCoVi ANR 18-CE16-0001-02, MitObesity ANR 18-CE14-0029-01, ORUPS ANR-16-CE37-0010-01 and BRAIN ANR-10-LABX-0043) (to G.M.); NIH/NIDA (1R21DA037678-01), Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2016-78114-R and RED2018-102576-T), Instituto de Salud Carlos III (CB16/10/00282), an EU BATCure grant (666918), Junta de Castilla y León (Escalera de Excelencia CLU-2017-03), Ayudas Equipos Investigación Biomedicina 2017 Fundación BBVA and Fundación Ramón Areces (to J.P.B.); Instituto de Salud Carlos III (PI18/00285; RD16/0019/0018), the European Regional Development Fund, the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement 686009), Junta de Castilla y León (IES007P17) and Fundación Ramón Areces to (A.A.); French State/ANR/IdEx (ANR-10-IDEX-03-02), Eu-Fp7 (FP7-PEOPLE-2013-IEF-623638) and Ramon y Cajal Investigator Program (RYC-2017-21776) (to A.B.-G.); FRM (SPF20121226369) (to R.S.); FRM (ARF20140129235) (to L.B.); Spanish Ministry of Science, Innovation and Universities (MCINU/FEDER; grants SAF2015-64945-R and RTI2018-095311-B-I00) (to M.G.); Canada Research Chair, Alzheimer Society of Canada—Brain Canada (17-09), Natural Sciences and Engineering Research Council (RGPIN-2015-05880), Canadian Breast Cancer Foundation (2015-317342), Canadian Health Research Institute (CIHR, 388808), New Brunswick Innovation Foundation, New Brunswick Health Research Foundation and Université de Moncton (to E.H.-C.); Basque Government (IT1230-19), Red de Trastornos Adictivos, Instituto de Salud Carlos III (ISC-III), European Regional Development Funds-European Union (ERDF-EU; RD16/0017/0012) and MINECO/FEDER, UE (SAF2015-65034-R) (to P.G.); University of the Basque Country PhD contract (PIF 16/251) (to S.A.); POP contract (BES-2016-076766, BES-C-2016-0051) (to I.B.-D.R.); French State/ANR (ANR-10-IDEX and TRAIL ANR-10-LABX-57); French-Swiss ANR-FNS (ANR-15- CE37-0012) (to A.-K.B.-S.); SFB/TRR 58 ‘Fear, anxiety, anxiety disorders’ (subproject A04); and CRC 1193 ‘Neurobiology of resilience’ (subproject B04) (to B.L.)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Differential control of cocaine self-administration by GABAergic and glutamatergic CB1 cannabinoid receptors

  • Martín García, Elena, 1975-
  • Bourgoin, Lucie
  • Cathala, Adeline
  • Kasanetz, Fernando
  • Mondesir, Miguel
  • Gutiérrez-Rodríguez, Ana
  • Reguero, Leire
  • Fiancette, Jean-François
  • Grandes, Pedro
  • Spampinato, Umberto
  • Maldonado, Rafael, 1961-
  • Piazza, Pier Vincenzo
  • Marsicano, Giovanni
  • Deroche-Gamonet, Véronique
The type 1 cannabinoid receptor (CB1) modulates numerous neurobehavioral processes and is therefore explored as a target for the treatment of several mental and neurological diseases. However, previous studies have investigated CB1 by targeting it globally, regardless of its two main neuronal localizations on glutamatergic and GABAergic neurons. In the context of cocaine addiction this lack of selectivity is critical since glutamatergic and GABAergic neuronal transmission is involved in different aspects of the disease. To determine whether CB1 exerts different control on cocaine seeking according to its two main neuronal localizations, we used mutant mice with deleted CB1 in cortical glutamatergic neurons (Glu-CB1) or in forebrain GABAergic neurons (GABA-CB1). In Glu-CB1, gene deletion concerns the dorsal telencephalon, including neocortex, paleocortex, archicortex, hippocampal formation and the cortical portions of the amygdala. In GABA-CB1, it concerns several cortical and non-cortical areas including the dorsal striatum, nucleus accumbens, thalamic, and hypothalamic nuclei. We tested complementary components of cocaine self-administration, separating the influence of primary and conditioned effects. Mechanisms underlying each phenotype were explored using in vivo microdialysis and ex vivo electrophysiology. We show that CB1 expression in forebrain GABAergic neurons controls mouse sensitivity to cocaine, while CB1 expression in cortical glutamatergic neurons controls associative learning processes. In accordance, in the nucleus accumbens, GABA-CB1 receptors control cocaine-induced dopamine release and Glu-CB1 receptors control AMPAR/NMDAR ratio; a marker of synaptic plasticity. Our findings demonstrate a critical distinction of the altered balance of Glu-CB1 and GABA-CB1 activity that could participate in the vulnerability to cocaine abuse and addiction. Moreover, these novel insights advance our understanding of CB1 neuropathophysiology., This work was supported by INSERM, the University of Bordeaux and the Aquitaine Region (to VDG, PVP, GM, UM), by the Fondation pour la Recherche Medicale (DRM20101220445), the Human Frontiers Science Program, and the Agence Nationale de la Recherche (ANR Blanc ANR-13BSV4–0006-02) (to GM), the DG Research of the European Commission FP7 [#HEALTH-F2 2013–602891 (to RM), HEALTH-60319 and ERC–2010–StG–260515 (to GM)], the Spanish ‘RETICS-Instituto de Salud Carlos III’ (#RD12/0028/0023), the Spanish ‘Ministerio de Ciencia e Innovación’ (#SAF2011–29864, no. SAF2011–29864, #SAF2013-40592-R, no. SAF2013-40592-R) and the Catalan Government ‘AGAUR-Generalitat de Catalunya’ (#2009SGR00731 and #2014-SGR-1547) (to RM), The Basque Government grant BCG IT764-13, Ministerio de Economía y Competitividad (MINECO) grant BFU2012-33334, University of the Basque Country UPV/EHU UFI11/41 and Red de Trastornos Adictivos - Instituto de Salud Carlos III grant RD12/0028/0004 (to PG). The FEDER funds support is also acknowledged. EM-G was supported by a ‘Sara Borrell’ post-doctoral fellowship from the Spanish ‘Instituto de Salud Carlos III’. FK was supported by an Aquitaine Region post-doctoral grant
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Peripheral and central CB1 cannabinoid receptors control stress-induced impairment of memory consolidation

  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Srivastava, Raj Kamal
  • Cutando Ruiz, Laura, 1985-
  • Ortega Alvaro, Antonio
  • Ruehle, Sabine
  • Remmers, Floortje
  • Bindila, Laura
  • Bellochio, Luigi
  • Marsicano, Giovanni
  • Lutz, Beat
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
Stressful events can generate emotional memories linked to the traumatic incident, but they also can impair the formation of nonemotional memories. Although the impact of stress on emotional memories is well studied, much less is known about the influence of the emotional state on the formation of nonemotional memories. We used the novel object-recognition task as a model of nonemotional memory in mice to investigate the underlying mechanism of the deleterious effect of stress on memory consolidation. Systemic, hippocampal, and peripheral blockade of cannabinoid type-1 (CB1) receptors abolished the stress-induced memory impairment. Genetic deletion and rescue of CB1 receptors in specific cell types revealed that the CB1 receptor population specifically in dopamine β-hydroxylase (DBH)-expressing cells is both necessary and sufficient for stress-induced impairment of memory consolidation, but CB1 receptors present in other neuronal populations are not involved. Strikingly, pharmacological manipulations in mice expressing CB1 receptors exclusively in DBH(+) cells revealed that both hippocampal and peripheral receptors mediate the impact of stress on memory consolidation. Thus, CB1 receptors on adrenergic and noradrenergic cells provide previously unrecognized cross-talk between central and peripheral mechanisms in the stress-dependent regulation of nonemotional memory consolidation, suggesting new potential avenues for the treatment of cognitive aspects on stress-related disorders., We acknowledge a predoctoral fellowship from the Spanish Ministry of Education and a postdoctoral fellowship from the Investments for the Future Programme, Initiative of Excellence Bordeaux, ANR-10-IDEX-03-02 (to A.B.-G.); a postdoctoral fellowship from the Marie Curie action Seventh Framework Programme for Research and Technological Development, FP7-PEOPLE-2013 (to A.B.-G.); the partial support by FRAXA Research Foundation (M.G.-G.); a European Molecular Biology Organization postdoctoral fellowship (to L. Bellocchio); grants from Ministerio de Ciencia e Innovación [BFU2012-33500 and BFU2015-68568P (to A.O.), and SAF2014-59648-P (to R.M.) (MINECO/FEDER, UE)]; Instituto de Salud Carlos III Grant RD06/0001/0001 (to R.M.); Generalitat de Catalunya Grant SGR-2014-1547 (to R.M.); ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia (R.M.); the German Research Council DFG Grants FOR926 (Core Unit Endocannabinoid Measurements) (to B.L.), CRC-TRR58 (to B.L.), and CRC1080 (to B.L.); EU-FP7 Grant REPROBESITY, HEALTH-F2-2008-223713 (to B.L. and G.M.); PainCage Grant HEALTH-2013-INNOVATION-1-603191 (to G.M.); INSERM (G.M.); European Research Council Grant ENDOFOOD, ERC–2010–StG–260515 (to G.M.); Fondation pour la Recherche Medicale (G.M.); Region Aquitaine (G.M.); and LABEX BRAIN Grant ANR-10-LABX-43 (to G.M.)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Dissociation of the pharmacological effects of THC by mTOR blockade

  • Puighermanal Puigvert, Emma, 1983-
  • Busquets Garcia, Arnau, 1985-
  • Gomis González, Maria, 1988-
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Ozaita Mintegui, Andrés, 1969-
The potential therapeutic benefits of cannabinoid compounds have raised interest in understanding the molecular mechanisms that underlie cannabinoid-mediated effects. We previously showed that the acute amnesic-like effects of delta9-tetrahydrocannabinol (THC) were prevented by the subchronic inhibition of the mammalian target of rapamycin (mTOR) pathway. In the present study, we assess the relevance of the mTOR pathway in other acute and chronic pharmacological effects of THC. The rapamycin derivative temsirolimus, an inhibitor of the mTOR pathway approved by the Food and Drug Administration, prevents both the anxiogenic- and the amnesic-like effects produced by acute THC. In contrast, THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception are not sensitive to the mTOR inhibition. In addition, a clear tolerance to THC-induced anxiolysis, hypothermia, hypolocomotion, and antinociception was observed after chronic treatment, but not to its anxiogenic- and amnesic-like effects. Temsirolimus pre-treatment prevented the amnesic-like effects of chronic THC without affecting the downregulation of CB1 receptors (CB1R) induced by this chronic treatment. Instead, temsirolimus blockade after chronic THC cessation did not prevent the residual cognitive deficit produced by chronic THC. Using conditional knockout mice lacking CB1R in GABAergic or glutamatergic neurons, we found that GABAergic CB1Rs are mainly downregulated under chronic THC treatment conditions, and CB1-GABA-KO mice did not develop cognitive deficits after chronic THC exposure. Therefore, mTOR inhibition by temsirolimus allows the segregation of the potentially beneficial effects of cannabinoid agonists, such as the anxiolytic and antinociceptive effects, from the negative effects, such as anxiogenic- and amnesic-like responses. Altogether, these results provide new insights for targeting the endocannabinoid system in order to prevent possible side effects., EP and AB-G were recipients of a predoctoral fellowship, Ministerio de Educación y Cultura. This work was supported by grants from the Ministerio de Ciencia e Innovación (#SAF2009-07309 to AO and # SAF2011-29864 to RM), Instituto de Salud Carlos III (RD06/0001/0001 to RM), PLAN E/n(Plan Español para el Estímulo de la Economía y el Empleo), the European Commission/n(PHECOMP #LSHM-CT-2007-037669 to RM), Generalitat de Catalunya (SGR-2009-00731/nto RM), INSERM to GM, European Research Council (ENDOFOOD, ERC-2010-StG-/n260515, to GM), Fondation pour la Recherche Medicale to GM, and ICREA (Institució Catalana de Recerca i Estudis Avançats) Academia to RM
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The endocannabinoid system in guarding against fear, anxiety and stress

  • Lutz, Beat
  • Marsicano, Giovanni
  • Maldonado, Rafael, 1961-
  • Hillard, Cecilia J.
The endocannabinoid (eCB) system has emerged as a central integrator linking the perception of external and internal stimuli to distinct neurophysiological and behavioural outcomes (such as fear reaction, anxiety and stress-coping), thus allowing an organism to adapt to its changing environment. eCB signalling seems to determine the value of fear-evoking stimuli and to tune appropriate behavioural responses, which are essential for the organism's long-term viability, homeostasis and stress resilience; and dysregulation of eCB signalling can lead to psychiatric disorders. An understanding of the underlying neural cell populations and cellular processes enables the development of therapeutic strategies to mitigate behavioural maladaptation., B.L. was supported by the German Research Foundation (SFB TRR 58, CRC 1080 and FOR 926); G.M. by the Institut national de la santé et de la recherche médicale (INSERM), the European Commission Seventh Framework Programme (REPROBESITY, HEALTH-F2-2008-223713, PAINCAGE and HEALTH-2014-603191), the European Research Council (Endofood, ERC-2010-StG−260515, CannaPreg and ERC-2014-PoC-640923), the Fondation pour la Recherche Medicale (DRM20101220445), the Human Frontiers Science Program, Region Aquitaine, Agence Nationale de la Recherche (ANR Blanc NeuroNutriSens ANR-13-BSV4-0006 and BRAIN ANR-10-LABX-0043); R.M. by the grants SAF2014-59648P, RETICS-RTA#RD12/0028/0023, AGAUR#2014-SGR-1547 and Health-F2-2013-602891; and C.J.H. by the US National Institutes of Health grants DA038663, DA026996 and MH102838.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pregnenolone can protect the brain from cannabis intoxication

  • Vallée, Monique
  • Martín García, Elena, 1975-
  • Maldonado, Rafael, 1961-
  • Piazza, Pier Vincenzo
Pregnenolone is considered the inactive precursor of all steroid hormones, and its potential functional effects have been largely uninvestigated. The administration of the main active principle of Cannabis sativa (marijuana), Δ(9)-tetrahydrocannabinol (THC), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (CB1) receptor. Pregnenolone then, acting as a signaling-specific inhibitor of the CB1 receptor, reduces several effects of THC. This negative feedback mediated by pregnenolone reveals a previously unknown paracrine/autocrine loop protecting the brain from CB1 receptor overactivation that could open an unforeseen approach for the treatment of cannabis intoxication and addiction., Supported by the EU-FP7 (REPROBESITY, HEALTH-F2-2008-223713, G.M.), the European Research Council (ENDOFOOD, ERC-2010-StG-260515, G.M.), the Agence Nationale pour la Recherche (contracts HICOMET and TIMMS, P.V.P.), the U.S. National Institutes of Health (NIH) (grants DA-03672, DA-003934, and DA-09789, R.A.R. and G.L.B., and RO1 DA003934 and KO5 DA021358, P.H.R.